Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

ABO-incompatible bone marrow transplantation.

M Wiesneth1, B Hertenstein, D Bunjes

  • 1Red Cross Blood Bank Ulm, FRG.

Beitrage Zur Infusionstherapie = Contributions to Infusion Therapy
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment of steroid-refractory acute/chronic graft versus host disease: A single-center real-world experience of ruxolitinib in combination with extracorporeal photopheresis in a high-risk population.

Leukemia research·2024
Same author

A resonance sonorheometry guided dose reduction of plasma transfusion in repetitive hip surgery in a patient with a severe factor XI deficiency: a case report.

Anaesthesia reports·2024
Same author

Randomized phase-III study of low-dose cytarabine and etoposide + /- all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia.

Scientific reports·2023
Same author

Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine.

Leukemia·2019
Same author

EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL).

Bone marrow transplantation·2019
Same author

Reduced-toxicity conditioning for allogeneic hematopoietic cell transplantation in elderly or comorbid patients with AML using fludarabine, BCNU and melphalan: disease stage at transplant determines outcome.

Bone marrow transplantation·2017
Same journal

[Not Available].

Beitrage zur Infusionstherapie = Contributions to infusion therapy·1993
Same journal

[Preliminary results of the 2nd multicenter study. Thrombocytapheresis with the Fresenius AS-104 blood cell separator and ring study of cell counting. Section of Therapeutic and Preparative Hemapheresis of the DGTI].

Beitrage zur Infusionstherapie = Contributions to infusion therapy·1993
Same journal

[Thrombocyte substitution in hematologic patients].

Beitrage zur Infusionstherapie = Contributions to infusion therapy·1993
Same journal

[Substitution of thrombocyte concentrates in polytransfused patients].

Beitrage zur Infusionstherapie = Contributions to infusion therapy·1993
Same journal

[Indications for fresh frozen plasma: evaluation of virus inactivating preparations].

Beitrage zur Infusionstherapie = Contributions to infusion therapy·1993
Same journal

[Indications for irradiated blood components: dose and side effects].

Beitrage zur Infusionstherapie = Contributions to infusion therapy·1993
See all related articles

Bone marrow transplantation (BMT) outcomes are not affected by ABO incompatibility. While erythrocyte reconstitution is delayed in major ABO-incompatible BMT, graft rejection, graft-versus-host disease, and survival rates remain similar.

Area of Science:

  • Hematology
  • Immunology
  • Transplantation Medicine

Background:

  • Bone marrow transplantation (BMT) is a critical treatment for hematologic malignancies and other diseases.
  • ABO compatibility between donor and recipient is a key consideration in BMT, though its impact on outcomes is debated.

Purpose of the Study:

  • To evaluate the influence of ABO incompatibility on hematopoietic recovery, graft rejection, graft-versus-host disease (GVHD), and survival after HLA-identical BMT.

Main Methods:

  • Retrospective analysis of 201 HLA-identical BMT cases over 10 years.
  • Categorization of BMT based on ABO compatibility (compatible, major incompatible, minor incompatible).
  • Assessment of granulocyte, platelet, and erythrocyte recovery, graft rejection, GVHD, relapse rates, and survival.

Related Experiment Videos

Main Results:

  • ABO compatibility did not impact granulocyte or platelet recovery.
  • Major ABO-incompatible BMT showed a significant delay (approx. 1 week) in erythrocyte reconstitution (p < 0.01).
  • Pure red cell aplasia occurred in 6/21 group O recipients of group A transplants.
  • Graft rejection, GVHD incidence, leukemic relapse rates, and 10-year survival were similar between ABO-compatible and incompatible BMT.

Conclusions:

  • ABO incompatibility does not significantly affect key outcomes of HLA-identical BMT, including survival.
  • Delayed erythrocyte recovery and rare cases of pure red cell aplasia are specific risks in major ABO-incompatible BMT.
  • These findings support the feasibility of ABO-incompatible BMT when HLA-identical donors are necessary.